Herbal Monograph
Rhodiola
Rhodiola rosea L.
Crassulaceae
The Arctic adaptogen — validated by Soviet-era research and modern clinical trials for stress resilience and mental performance.
Overview
Plant Description
Perennial succulent herbaceous plant, dioecious (separate male and female plants), 5-40 cm tall. Rhizome thick, fleshy, cylindrical to irregularly branched, 2-5 cm in diameter, covered with a golden to bronze-colored scaly outer bark (cork layer); interior white to rose-pink when freshly cut, with a characteristic rose-like fragrance when broken (hence the species name 'rosea'). Multiple erect, unbranched stems arise from the rhizome crown. Leaves alternate, sessile, oblong-elliptic to obovate, 1-4 cm long, fleshy (succulent), glaucous blue-green, with irregularly serrate to dentate margins on the upper portion. Flowers small, 4-merous, borne in dense terminal corymbose cymes; sepals yellow-green, petals yellow to greenish-yellow (male flowers) or reddish to purplish (female flowers). Male flowers have 8 stamens exceeding the petals. Female flowers develop 4 erect follicles that turn reddish at maturity. Fruit consists of 4 divergent reddish-brown follicles containing tiny dust-like seeds. Flowering occurs May-August depending on latitude and altitude.
Habitat
Arctic and alpine regions of Europe, Asia, and North America. Found on rocky ledges, cliff faces, sea cliffs, mountain screes, and high-altitude meadows. Prefers well-drained, sandy or rocky soils. Tolerates extreme cold (to -40C), high winds, and intense UV radiation. Grows from sea level (in arctic regions) to 4500 m altitude (in Central Asian mountain ranges). Typically found above treeline. Requires cold winters for dormancy and performs poorly in warm, humid lowland conditions.
Distribution
Circumboreal-alpine distribution. Scandinavia (Norway, Sweden, Finland, Iceland), British Isles (Scotland, Ireland, Wales), Alps, Pyrenees, Carpathians, Balkans, Urals, Altai Mountains, Siberia, Central Asia (Tien Shan, Pamir), Mongolia, northern China (Xinjiang, Tibet), Korea, and Arctic North America (Alaska, northern Canada, Greenland). Russia (particularly Siberia and the Altai Mountains) has historically been the primary source of wild-harvested material. Currently wild populations are declining due to overharvesting and are legally protected in several countries (Russia, UK, Czech Republic, Bosnia-Herzegovina). Commercial cultivation is expanding in Scandinavia, Canada, and parts of Europe.
Parts Used
Root and rhizome (Rhizoma et Radix Rhodiolae roseae)
Preferred: Dried powdered rhizome (capsule), standardized extract (SHR-5 type), tincture, dried slices for decoction
The underground portions (thick fleshy rhizome and attached roots) constitute the sole medicinal part. The characteristic rose-like fragrance of the freshly cut rhizome is a traditional marker of authenticity. Both rosavin (the phenylpropanoid marker unique to R. rosea) and salidroside (the phenylethanoid glycoside shared with other Rhodiola species) are concentrated in the root and rhizome. Aerial parts are not used medicinally, though they contain minor amounts of flavonoids. The ratio of rosavins to salidroside (approximately 3:1) has become the de facto standardization benchmark based on the composition of the clinically studied SHR-5 extract.
Key Constituents
Rosavins (phenylpropanoid glycosides — marker compounds unique to R. rosea)
Rosavins are the signature phenylpropanoid glycosides that distinguish Rhodiola rosea from all other Rhodiola species. They serve as both taxonomic markers and quality/standardization benchmarks. The SHR-5 extract (used in the majority of clinical trials) is standardized to a minimum 3% rosavins and 1% salidroside, reflecting the naturally occurring approximately 3:1 ratio in authentic R. rosea rhizome. Preclinical evidence suggests rosavins contribute to anti-depressant and adaptogenic activity, possibly through modulation of monoamine neurotransmitter levels. However, the therapeutic effect of R. rosea is likely due to the synergistic action of rosavins, salidroside, and other constituents rather than any single compound.
Phenylethanoid glycosides
Salidroside is considered a primary bioactive constituent responsible for many of the neuroprotective, anti-fatigue, and adaptogenic effects of Rhodiola. Extensive preclinical literature demonstrates its ability to protect neurons from oxidative stress, enhance mitochondrial function, modulate cortisol release, and improve cognitive function under stress conditions. It is the constituent most directly linked to the herb's adaptogenic mechanism: normalizing the stress response by modulating the HPA axis and cellular stress-resistance pathways (including heat shock proteins Hsp70 and cortisol regulation). Salidroside alone, however, does not fully replicate the clinical effects of whole R. rosea extract, supporting a synergistic model of activity.
Flavonoids
Flavonoids in Rhodiola contribute to the herb's antioxidant and anti-inflammatory profile. Herbacetin-type flavonoids (rhodionin, rhodiolin, rhodioflavonoside) are relatively specific to R. rosea and serve as additional authentication markers. Their individual pharmacological contribution is likely modest compared to rosavins and salidroside, but they participate in the multi-target polypharmacology characteristic of adaptogenic herbs.
Monoterpenes
Monoterpenes contribute to the characteristic aroma of the rhizome and may have pharmacological significance. Rosiridol's in vitro MAO-inhibitory activity is of particular interest given the herb's traditional use for mood enhancement and modern clinical application in mild depression. However, the clinical significance of these monoterpenes at typical oral doses remains to be established.
Phenolic acids and other constituents
Phenolic acids and other minor constituents contribute to the overall antioxidant capacity of R. rosea extracts. They are not considered primary active constituents but participate in the complex multi-compound pharmacology of the whole extract. The presence and proportions of these compounds vary by geographic origin and are part of the phytochemical fingerprint used in quality assessment.
Herbal Actions
Helps the body adapt to stress and restore homeostasis
The defining pharmacological action of Rhodiola rosea and the basis for most clinical applications. Adaptogens are defined as agents that increase non-specific resistance to stress, normalize physiological functions regardless of the direction of change, and cause minimal side effects (Brekhman & Dardymov 1969; Panossian & Wikman 2010). R. rosea modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing excessive cortisol release during acute stress while supporting adrenal function during chronic stress. Demonstrated to upregulate molecular chaperones (Hsp70, Hsp72), activate AMPK pathway, modulate neuropeptide Y, and influence serotonin and dopamine metabolism. Multiple RCTs demonstrate reduced perception of fatigue and improved performance under stress conditions. The SHR-5 standardized extract is the most clinically validated adaptogenic Rhodiola preparation.
[9, 19, 20]Reduces anxiety
Rhodiola demonstrates clinically significant anxiolytic effects in subjects with generalized anxiety and stress-related anxiety. Bystritsky et al. 2008 pilot study found significant reduction in Hamilton Anxiety Rating Scale scores with R. rosea extract (340 mg/day). Proposed mechanisms include modulation of serotonin (5-HT) and GABA pathways, HPA axis normalization, and reduction of cortisol-mediated anxiety. The anxiolytic effect appears to be dose-dependent: lower doses (200-340 mg/day) tend to be more anxiolytic and calming, while higher doses can be more stimulating.
[12, 13]Reduces inflammation
Salidroside and rosavin both demonstrate anti-inflammatory activity in preclinical models, including inhibition of NF-kB signaling, reduction of COX-2 expression, and suppression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Salidroside inhibits phosphodiesterase and modulates inflammatory cascades. Anti-inflammatory activity is considered a contributing mechanism to the herb's adaptogenic and neuroprotective effects rather than a standalone clinical application. Less potent as a direct anti-inflammatory compared to herbs like turmeric or willow bark.
[20, 21]Prevents or slows oxidative damage to cells
R. rosea extract demonstrates significant free radical scavenging and antioxidant activity in both in vitro and animal studies. Salidroside protects against oxidative stress-induced cell damage, particularly in neuronal and cardiac tissue. Polyphenols, flavonoids, and organic acids contribute to overall antioxidant capacity. The antioxidant effect is considered one of several mechanisms underlying the neuroprotective and adaptogenic actions.
[19]Enhances cognitive function, memory, and mental performance
One of the most clinically substantiated actions of R. rosea. Multiple RCTs demonstrate improved cognitive function under stress and fatigue conditions. Darbinyan et al. 2000 RCT found improved mental performance, particularly associative thinking, short-term memory, calculation, and speed of audiovisual perception during fatigue. Shevtsov et al. 2003 single-dose study showed improved cognitive function and reduced mental fatigue during night duty. Proposed mechanisms include enhanced dopaminergic and serotonergic neurotransmission, increased cerebral blood flow, and neuroprotection against stress-induced cognitive decline. Importantly, cognitive enhancement is most pronounced under conditions of stress or fatigue, consistent with adaptogenic rather than stimulant activity.
[4, 5, 6]Modulates and balances immune function
Preclinical evidence demonstrates that salidroside and R. rosea extracts modulate immune function: enhancing NK cell activity, stimulating T-lymphocyte proliferation, and regulating cytokine balance. The immunomodulatory activity appears to be bidirectional (enhancing suppressed immunity, moderating overactive inflammatory responses), consistent with the adaptogenic profile. Clinical evidence for direct immunomodulatory effects in humans is limited to indirect markers (reduced illness frequency in stressed populations).
[20]Supports and calms the nervous system
R. rosea supports nervous system function through multiple mechanisms: modulation of monoamine neurotransmitters (serotonin, dopamine, norepinephrine), beta-endorphin release, and neuroprotection against oxidative and excitotoxic damage. The nervine action encompasses both the nootropic (cognitive) and mood-regulating effects. Rosiridol demonstrates MAO-A and MAO-B inhibitory activity in vitro (van Diermen et al. 2009), though clinical significance at oral doses is uncertain. The overall nervine effect is tonic and restorative rather than sedative.
[19, 22]Therapeutic Indications
Endocrine System
Stress-related fatigue and burnout (adrenal fatigue, chronic stress syndrome)
The primary clinical indication for R. rosea and the most extensively studied. Olsson et al. 2009 RCT (n=60, burnout patients): SHR-5 extract (576 mg/day, 28 days) significantly improved attention, cortisol awakening response, and self-reported burnout symptoms. Lekomtseva et al. 2017 RCT (n=118, stress-related fatigue): 400 mg/day R. rosea extract significantly improved fatigue, exhaustion, and impaired concentration from week 1. Edwards et al. 2012 (n=101, prolonged stress): significant improvements in stress symptoms, disability, functional impairment, and quality of life. Mechanism involves HPA axis normalization, cortisol modulation, and enhancement of cellular energy metabolism (AMPK activation).
[9, 10, 11]HPA axis dysregulation from chronic stress
R. rosea modulates the HPA axis stress response, as demonstrated by effects on salivary cortisol in clinical trials. Olsson et al. 2009 found normalization of the cortisol awakening response in burnout patients after 28 days of SHR-5. Preclinical studies demonstrate that salidroside modulates corticotropin-releasing hormone (CRH) and ACTH signaling. The adaptogenic model proposes that R. rosea acts as a 'stress-response modifier' — not suppressing cortisol outright but preventing excessive or prolonged cortisol elevation while supporting adequate cortisol response when needed.
[9, 20]Nervous System
Cognitive dysfunction under stress and fatigue (mental performance enhancement)
Multiple RCTs demonstrate improved cognitive performance under stress or fatigue conditions. Darbinyan et al. 2000 RCT (n=56, physicians during night duty): single dose of SHR-5 extract (170 mg) significantly improved associative thinking, short-term memory, calculation, and audiovisual perception compared to placebo (P<0.01). Shevtsov et al. 2003 RCT (n=161, military cadets during night duty): single dose (370 or 555 mg) significantly improved anti-fatigue index and mental work capacity. Spasov et al. 2000 RCT (n=40, medical students during exam period): improved mental performance, psychomotor function, physical fitness, and general well-being. Effects are most pronounced during conditions of stress, fatigue, or sleep deprivation — consistent with an adaptogenic rather than a pure stimulant mechanism.
[4, 5, 6]Mild to moderate depression
Darbinyan et al. 2007 RCT (n=89): R. rosea extract (SHR-5, 340 or 680 mg/day, 6 weeks) significantly improved Hamilton Depression Rating Scale (HAMD) scores compared to placebo. Both doses improved depression, insomnia, and emotional instability; the higher dose also improved self-esteem. Mao et al. 2015 RCT (n=57): R. rosea extract (340 mg/day) compared with sertraline (50 mg/day) and placebo over 12 weeks. R. rosea showed less improvement in HAMD than sertraline (P=0.007 vs P<0.001) but significantly fewer adverse effects, yielding a better overall risk-benefit ratio. Proposed mechanisms include modulation of serotonin and dopamine via inhibition of MAO-A (van Diermen et al. 2009), increased beta-endorphin levels, and HPA axis normalization.
[7, 8, 22]Generalized anxiety disorder (mild to moderate)
Bystritsky et al. 2008 pilot RCT (n=10): 340 mg/day R. rosea for 10 weeks resulted in significant reduction in Hamilton Anxiety Rating Scale scores. Cropley et al. 2015 RCT (n=80): 200 mg/day R. rosea for 14 days improved self-reported anxiety, stress, anger, confusion, and depression in a mildly anxious population. Evidence is preliminary due to small sample sizes, but consistent direction of effect across studies. Lower doses (200-340 mg/day) appear to be more effective for anxiolytic activity than higher, potentially stimulating doses.
[12, 13]Immune System
Stress-related immunosuppression (increased susceptibility to illness during chronic stress)
Preclinical evidence shows salidroside enhances NK cell activity, T-lymphocyte proliferation, and macrophage function. In clinical trials of stress and fatigue, reduced frequency of illness during supplementation periods has been reported as a secondary outcome, though this has not been a primary endpoint in well-designed RCTs. The immunomodulatory effect is considered secondary to HPA axis normalization — by reducing chronic stress-mediated cortisol elevation, R. rosea may indirectly support immune function.
[20]Cardiovascular System
Stress-related cardiovascular risk (elevated heart rate and blood pressure under stress)
R. rosea has demonstrated cardioprotective effects in preclinical models, including protection against ischemia-reperfusion injury and stress-induced cardiac arrhythmia. Salidroside protects cardiomyocytes from oxidative damage and apoptosis. Some clinical trials have reported normalization of heart rate and blood pressure as secondary outcomes in stressed populations. Direct cardiovascular indications are not well-established clinically, but the herb's stress-modulating effects may contribute to cardiovascular risk reduction in chronically stressed individuals.
[19]Musculoskeletal System
Physical performance and endurance under stress
Extensive use in Soviet and Russian sports medicine for enhancing physical performance and recovery. De Bock et al. 2004 RCT: R. rosea (200 mg/day, 4 weeks) significantly improved endurance exercise capacity (time to exhaustion) in young, healthy volunteers. Parisi et al. 2010 found improved antioxidant capacity and reduced markers of muscle damage after exhaustive exercise. However, not all exercise studies have been positive — some well-designed trials in trained athletes showed no ergogenic benefit. Effects appear most pronounced in conditions of fatigue, stress, or submaximal performance rather than in well-rested elite athletes at peak performance.
[5, 14]Energetics
Temperature
slightly warm
Moisture
dry
Taste
Tissue States
cold/depression, damp/stagnation, wind/tension (with agitation from stress)
Rhodiola is considered slightly warm and drying in Western energetic terms, though it is notably milder in thermal quality than strongly warming adaptogens like Eleutherococcus or ginger. Its primary energetic action is to restore vitality and resilience in states of exhaustion, depletion, and stress-induced depression. It is best suited for individuals with a cold, depleted, or stagnant constitution — those experiencing burnout, fatigue, and mental fog. Caution in individuals with a hot, agitated constitution or in cases of mania/hypomania. In TCM terms (as Hong Jing Tian, though this name more commonly refers to R. crenulata), it is classified as sweet and slightly cold in some sources, or sweet and neutral in others, entering the Lung and Heart channels — used to invigorate blood circulation, tonify qi, and clear lung heat. The TCM categorization differs from the Western energetic reading, which is common for adaptogens that have bidirectional regulatory effects. In Siberian and Russian folk tradition, it is considered a warming tonic for cold climates, used to sustain physical and mental endurance through harsh winters.
Traditional Uses
Scandinavian and Viking Traditional Medicine
- General tonic for physical endurance and mental stamina in harsh arctic conditions
- Enhancement of physical strength and work capacity for manual labor and seafaring
- Treatment of cold-related illnesses and recovery from winter debility
- Mountain sickness and altitude adaptation
- Headache and 'nervous' conditions
"Rhodiola has been used in Scandinavian folk medicine for over 1000 years. Viking warriors reportedly consumed golden root to enhance physical strength and endurance. Linnaeus (1749) documented its use in Swedish folk medicine for headaches and 'hysteria'. The Swedish Pharmacopoeia included Rhodiola rosea as early as 1755. In Iceland and Norway, the root was used as a general tonic, especially during the long, dark winters. The Finnish used it as a food in soups and stews during times of scarcity, as well as medicinally."
Russian and Soviet Traditional/Military Medicine
- Official adaptogen for military personnel, cosmonauts, Olympic athletes, and political leaders
- Enhancement of physical work capacity and recovery from strenuous exercise
- Improvement of mental performance, memory, and concentration
- Protection against stress, fatigue, and high-altitude sickness
- Treatment of depression, fatigue, and neurasthenia
- Prevention of infectious illness during periods of intense stress
- Enhancement of sexual function
"The most extensive systematic research on Rhodiola began in the Soviet Union in the 1960s-1980s under classified military research programs. Soviet scientists, led by Dr. Nikolai Lazarev (who coined the term 'adaptogen') and later by Drs. Israel Brekhman and Alexander Saratikov, conducted extensive pharmacological and clinical research. R. rosea was included in the USSR's official State Pharmacopoeia and was provided to Soviet Olympic athletes, military special forces, and cosmonauts. Much of this early research was published in Russian and remained inaccessible to Western science for decades. Brown et al. (2002) and Panossian & Wikman (2010) have provided comprehensive English-language reviews of this Soviet-era research tradition."
Traditional Chinese Medicine (TCM)
- Hong Jing Tian: Invigorate blood circulation and resolve blood stasis
- Tonify qi and strengthen the body
- Clear lung heat and relieve cough (particularly at high altitude)
- Treat altitude sickness and high-altitude pulmonary edema
- Support recovery from chronic illness and debility
"In TCM, 'Hong Jing Tian' more commonly refers to Rhodiola crenulata and related Chinese Rhodiola species rather than R. rosea specifically, as R. rosea's natural range barely extends into northwestern China. However, the Rhodiola genus is used in Tibetan and Chinese medicine for blood-invigorating and qi-tonifying effects. Classified as sweet, slightly cold (or neutral depending on the source), entering the Lung and Heart channels. Listed in the Chinese Pharmacopoeia for activating blood circulation, tonifying qi, nourishing the lungs, and calming the heart-mind (shen). Used particularly for high-altitude adaptation in Tibetan medicine."
[19]
Siberian and Central Asian Folk Medicine
- General physical and mental tonic for surviving harsh winters
- Treatment of fatigue, weakness, and 'lack of vital force'
- Enhancement of fertility and sexual function
- Gift to newlywed couples to promote healthy offspring
- Treatment of colds, flu, and tuberculosis
- External application as poultice for wounds and skin conditions
- Tea from the root as a daily health tonic
"In Siberian folk tradition, the location of wild golden root patches was a closely guarded family secret. The root was traded along mountain paths and was considered as valuable as gold — hence the common name 'golden root'. In the Altai Mountains, a traditional saying held that 'those who drink golden root tea will be healthy and live to more than 100 years.' The root was given to couples before marriage to ensure fertility and healthy children. Mongolian traditional medicine used Rhodiola species for tuberculosis and related lung conditions."
Modern Research
Systematic review of Rhodiola rosea for physical and mental fatigue
Comprehensive systematic review of the efficacy and safety of Rhodiola rosea preparations for treatment of physical and mental fatigue, based on available randomized controlled trials and controlled clinical trials.
Findings: The review identified 11 clinical trials meeting inclusion criteria. Evidence supported a beneficial effect of R. rosea on physical performance, mental performance, and certain mental health conditions. Adaptogenic effects were consistently demonstrated: reduced fatigue perception, improved cognitive function under stress, and normalization of stress biomarkers. SHR-5 extract (standardized to 3% rosavins, 1% salidroside) was the most frequently studied preparation. Effects were most consistent for mental fatigue and stress-related cognitive impairment.
Limitations: Heterogeneity in study designs, doses, preparations, and outcome measures. Several studies were small (n<50). Many of the older Russian studies had methodological limitations by modern standards. Publication bias could not be excluded. The authors noted a need for larger, well-designed confirmatory trials.
[15]
RCT of Rhodiola rosea for stress-related fatigue (burnout)
Double-blind, placebo-controlled, parallel-group RCT of 60 patients with stress-related fatigue (burnout syndrome). Participants received SHR-5 extract (576 mg/day) or placebo for 28 days.
Findings: R. rosea significantly improved attention (d2 test of attention), cortisol awakening response, and self-reported burnout symptoms compared to placebo. The cortisol response was more normalized (improved awakening cortisol peak) in the R. rosea group, suggesting modulation of HPA axis function. Improvements were noted from week 1 with continued benefit through week 4. No significant adverse effects.
Limitations: Moderate sample size (n=60). Short treatment duration (28 days). Single-center study. Burnout is not a standardized psychiatric diagnosis, introducing heterogeneity in the study population.
[9]
RCT comparing Rhodiola rosea with sertraline for major depressive disorder
Phase 2 randomized, double-blind, three-arm trial comparing R. rosea extract (340 mg/day), sertraline (50 mg/day), and placebo in 57 adults with mild to moderate major depressive disorder (MDD) over 12 weeks.
Findings: Both R. rosea and sertraline showed improvement in HAMD scores compared to placebo, though only sertraline reached statistical significance vs. placebo (P<0.001 sertraline; P=0.014 R. rosea). The HAMD reductions were comparable in magnitude: R. rosea -8.2 points, sertraline -10.3 points, placebo -5.5 points. Critically, R. rosea had significantly fewer adverse effects than sertraline (30% vs 63% reporting at least one side effect, P=0.012). The authors concluded that R. rosea had a more favorable risk-benefit ratio than sertraline despite a slightly smaller clinical effect.
Limitations: Small sample size (n=57) limiting statistical power. Study was designed as a Phase 2 trial, not a definitive efficacy trial. Sertraline was used at minimum therapeutic dose (50 mg). No dose escalation. 12-week duration may be insufficient for some patients. High variability in HAMD scores.
[8]
RCT of Rhodiola rosea for cognitive function during physician fatigue
Double-blind, placebo-controlled crossover RCT of 56 healthy young physicians on night duty. Participants received a single dose of SHR-5 extract (170 mg) or placebo before a night shift, with cognitive performance tested before and after the shift.
Findings: R. rosea significantly improved total mental performance (complex perceptive and cognitive cerebral functions) during the first 2-week period by approximately 20% compared to placebo (P<0.01). Improvements were significant for associative thinking, short-term memory, calculation, and speed of audiovisual perception. However, the effect was not maintained in the second test period of the crossover design, possibly due to progressive fatigue or adaptation.
Limitations: Single-dose study design limits conclusions about sustained use. Crossover design showed attenuation in the second period (possible period effect). Relatively small sample. Specific to acute fatigue during night duty — not generalizable to chronic fatigue or neurodegenerative conditions.
[4]
RCT of Rhodiola rosea for mild to moderate depression
Randomized, double-blind, placebo-controlled trial of 89 patients with mild to moderate depression. Three groups: R. rosea SHR-5 340 mg/day, R. rosea SHR-5 680 mg/day, or placebo for 6 weeks.
Findings: Both R. rosea dose groups showed significant improvements in Hamilton Depression Rating Scale (HAMD) scores compared to placebo (P<0.01). Both doses significantly improved depression, insomnia, and emotional instability. The 680 mg/day dose additionally improved self-esteem. Overall Depression scores (Beck Depression Inventory) also improved significantly in both treatment groups. No clinically significant adverse effects observed.
Limitations: Six-week duration is relatively short for depression trials. No active comparator. Primarily conducted in one country (Armenia). Modest sample size per group (~30). Mechanism of anti-depressant action not fully elucidated.
[7]
Systematic review of adaptogens including Rhodiola rosea
Comprehensive systematic review of the evidence for adaptogenic herbs, with particular focus on Rhodiola rosea, Eleutherococcus senticosus, and Schisandra chinensis. Reviews molecular mechanisms, clinical evidence, and safety data.
Findings: R. rosea was identified as the adaptogen with the most robust clinical evidence base. Proposed molecular mechanisms for adaptogenic activity include: modulation of the HPA axis and cortisol response, upregulation of heat shock proteins (Hsp70), activation of AMPK and downstream energy metabolism pathways, modulation of nitric oxide and cortisol levels, and enhancement of neuropeptide Y signaling. The review concluded that adaptogens work primarily by modulating the stress-response system at multiple levels rather than through a single pharmacological target.
Limitations: Narrative/systematic review format; not a quantitative meta-analysis. Quality of included studies was variable. Many older studies had methodological limitations. The authors acknowledged the need for standardized clinical trial designs for adaptogen research.
Rhodiola rosea for physical endurance: double-blind RCT
Double-blind, placebo-controlled RCT of 24 young, healthy volunteers receiving R. rosea extract (200 mg/day, standardized to 1% rosavin) or placebo for 4 weeks, followed by acute exercise testing.
Findings: R. rosea supplementation significantly improved endurance exercise capacity. Time to exhaustion during cycling was significantly increased in the Rhodiola group. VO2 peak and VCO2 peak were also significantly improved. Pulmonary ventilation during exercise was enhanced. The authors attributed the effect to enhanced oxygen utilization and reduced perception of effort.
Limitations: Small sample size (n=24). Used a non-standard extract (not SHR-5) with lower rosavin standardization (1% vs typical 3%). Young healthy subjects may not represent the broader target population. Single-center study. Potential for publication bias.
[14]
Rhodiola rosea for generalized anxiety: pilot study
Open-label pilot study of 10 participants with generalized anxiety disorder (GAD) treated with R. rosea extract (340 mg/day) for 10 weeks.
Findings: Significant reductions in Hamilton Anxiety Rating Scale scores were observed (mean reduction of 6.7 points from baseline, P<0.01). Improvements were also seen in Clinical Global Impression of Severity and self-reported anxiety measures. The extract was well-tolerated with no serious adverse effects.
Limitations: Very small sample size (n=10). Open-label design (no placebo control or blinding). Single-arm with no comparator. Pilot study only — results require confirmation in larger controlled trials. GAD diagnosis was clinical; structured diagnostic interview may have improved diagnostic precision.
[12]
Preparations & Dosage
Standardized Extract
Strength: Standardized to 3% rosavins and 1% salidroside (SHR-5 type)
The most clinically studied form. The SHR-5 extract (Swedish Herbal Institute) is standardized to a minimum 3% rosavins and 1% salidroside, reflecting the natural ratio in authentic R. rosea rhizome. Commercially available as capsules or tablets.
200-600 mg/day of standardized extract (3% rosavins, 1% salidroside). For stress-related fatigue and cognitive enhancement: 200-400 mg/day. For mild depression: 340-680 mg/day. For acute performance (single dose): 200-680 mg taken 30-60 minutes before the stressful event.
Once daily (morning) or divided into two doses (morning and early afternoon). Avoid evening dosing due to potential stimulant effects that may interfere with sleep.
Clinical trials have studied durations of 1 day (acute) to 12 weeks. Traditional use is often cyclic: 2-3 months on, 1 month off. Long-term continuous use (>12 weeks) has not been well-studied but is practiced clinically.
Not established. Insufficient data for children and adolescents.
This is the recommended form for clinical use based on the preponderance of clinical trial evidence. The 3:1 rosavin-to-salidroside ratio is the established standardization benchmark. Products standardized only to salidroside (without rosavins) may contain other Rhodiola species (R. crenulata) and should not be considered equivalent. Morning dosing is preferred; many practitioners recommend taking on an empty stomach 20-30 minutes before breakfast for optimal absorption. A biphasic dose-response has been reported: lower doses (200-340 mg) tend to be more calming/anxiolytic, while higher doses (400-680 mg) tend to be more stimulating and energizing.
capsule-powder
Strength: Whole powdered dried root and rhizome, 500 mg-1 g per capsule
Fill capsules with finely powdered dried R. rosea root and rhizome. This is a simpler preparation than standardized extract, providing the full spectrum of root constituents without concentration.
500 mg-1.5 g powdered dried root per day, in divided doses. Some traditional sources recommend up to 2 g/day.
1-2 times daily, morning and early afternoon
As per standardized extract recommendations. Cyclic use (2-3 months on, 1 month off) is traditional.
Not established
Less precisely dosed than standardized extracts. Rosavin and salidroside content will vary by source, harvest, and processing. Authentic R. rosea root powder should have a characteristic rose-like aroma when the capsule is opened. May be appropriate for traditional use or when standardized products are unavailable, but standardized extracts are preferred for therapeutic applications based on clinical evidence.
[16]
Tincture
Strength: 1:5, 40-70% ethanol
Macerate dried R. rosea root in 40-70% ethanol at a ratio of 1:5 for 4-6 weeks. Shake regularly. Press and filter. Some traditional Russian preparations use 40% vodka as the menstruum.
2-4 mL (approximately 40-80 drops), 1-2 times daily
1-2 times daily, morning and early afternoon. Avoid evening dosing.
As per general R. rosea recommendations. Cyclic use recommended.
Not established. Alcohol-based preparations not recommended for children.
Traditional preparation method, particularly in Russian folk medicine (where vodka-macerated golden root was a household remedy). The alcohol effectively extracts both hydrophilic (salidroside, rosavins) and lipophilic (monoterpenes, essential oil) constituents. Tincture quality depends heavily on the authenticity and quality of the starting material. The tincture should have a golden to amber color and a characteristic rose-like, slightly astringent taste.
Decoction
Strength: 3-5 g dried root per 400-500 mL water
Simmer 3-5 g of dried R. rosea root slices in 400-500 mL of water for 15-20 minutes. Strain and drink warm.
200-250 mL, 1-2 times daily
1-2 times daily, morning and/or early afternoon
Traditional cyclic use. May be used daily for several weeks.
Not established
Traditional Siberian and Russian preparation. Decoction extracts the water-soluble glycosides (salidroside, rosavins) effectively but may lose volatile monoterpenes during prolonged simmering. The resulting tea has a distinctive golden color with a somewhat bitter, astringent, and slightly rose-like flavor. In Siberian folk tradition, the decoction was drunk in the morning as a daily tonic, particularly during winter months.
Infusion (Tea)
Strength: 2-3 g dried root per 250 mL water
Steep 2-3 g of dried, thinly sliced or coarsely powdered R. rosea root in 250 mL of just-boiled water for 15-20 minutes, covered. Strain and drink.
1-2 cups daily
1-2 times daily, preferably morning
As needed; may be used daily for several weeks as a tonic
Not established
A gentler preparation than decoction. The covered infusion retains some volatile aromatics. Less concentrated than decoction — may be preferred for mild daily tonic use. In Scandinavian folk practice, rhodiola root was sometimes combined with other Nordic herbs in health-promoting teas.
[16]
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Allergic reactions to Rhodiola are rare but theoretically possible. Discontinue use if allergic symptoms occur.
Due to Rhodiola's stimulatory and monoamine-modulating effects, there is a theoretical risk of triggering or exacerbating manic episodes in individuals with bipolar disorder. While no cases have been published in the literature, the pharmacological profile (MAO inhibition, dopaminergic and serotonergic enhancement) warrants caution. Use only under medical supervision in individuals with bipolar spectrum disorders.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| SSRI/SNRI antidepressants (fluoxetine, sertraline, venlafaxine, etc.) (Selective serotonin reuptake inhibitors / Serotonin-norepinephrine reuptake inhibitors) | theoretical | R. rosea modulates serotonergic and noradrenergic neurotransmission. Rosiridol and other constituents demonstrate in vitro MAO-A inhibitory activity. Theoretical risk of additive serotonergic effects when combined with SSRIs/SNRIs. Serotonin syndrome is a theoretical but unconfirmed risk. |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline) (Monoamine oxidase inhibitors) | theoretical | Rosiridol demonstrates dose-dependent inhibition of MAO-A and MAO-B in vitro (van Diermen et al. 2009). Combining with pharmaceutical MAO inhibitors could theoretically result in excessive monoamine accumulation. |
| Stimulant medications (methylphenidate, amphetamines, modafinil) (CNS stimulants) | theoretical | Rhodiola has mild CNS stimulatory properties. Additive stimulation with pharmaceutical stimulants could theoretically result in excessive sympathetic activation (increased heart rate, blood pressure, anxiety, insomnia). |
| Antidiabetic medications (insulin, metformin, sulfonylureas) (Hypoglycemic agents) | theoretical | Some preclinical evidence suggests R. rosea may have mild hypoglycemic effects through AMPK activation. Additive blood glucose lowering is theoretically possible. |
| Antihypertensive agents (Antihypertensive agents) | theoretical | R. rosea may have mild blood pressure-modulating effects. Theoretically could have additive hypotensive effects in some individuals, or mild hypertensive effects (via stimulatory action) in others. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
Pregnancy: No human clinical trials of R. rosea during pregnancy have been conducted. Animal reproductive toxicity studies are limited. In the absence of adequate safety data, R. rosea is not recommended during pregnancy as a precautionary measure. The adaptogenic and hormonal-modulating effects provide additional theoretical reasons for caution. Some traditional sources considered Rhodiola safe during pregnancy, but this has not been validated by modern research. Lactation: No data on the excretion of R. rosea constituents in breast milk. Due to the stimulatory potential and the absence of lactation-specific safety data, use during breastfeeding is not recommended until further data are available.
Adverse Effects
References
Monograph Sources
- [1] Committee on Herbal Medicinal Products (HMPC), European Medicines Agency. Assessment report on Rhodiola rosea L., rhizoma et radix. European Medicines Agency (2012)
- [2] National Center for Complementary and Integrative Health (NCCIH). Rhodiola. NCCIH, National Institutes of Health (2023)
- [3] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4 (draft): Rhizoma et Radix Rhodiolae Roseae. World Health Organization, Geneva (2009)
Clinical Studies
- [4] Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue — a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine (2000) ; 7 : 365-371 . DOI: 10.1016/S0944-7113(00)80055-0 . PMID: 11081987
- [5] Shevtsov VA, Zholus BI, Shervarly VI, Vol'skij VB, Korovin YP, Khristich MP, Roslyakova NA, Wikman G. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine (2003) ; 10 : 95-105 . DOI: 10.1078/094471103321659780 . PMID: 12725561
- [6] Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine (2000) ; 7 : 85-89 . DOI: 10.1016/S0944-7113(00)80078-1 . PMID: 10839209
- [7] Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmstrom C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry (2007) ; 61 : 343-348 . DOI: 10.1080/08039480701643290 . PMID: 17990195
- [8] Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine (2015) ; 22 : 394-399 . DOI: 10.1016/j.phymed.2015.01.010 . PMID: 25837277
- [9] Olsson EM, von Scheele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med (2009) ; 75 : 105-112 . DOI: 10.1055/s-0028-1088346 . PMID: 19016404
- [10] Edwards D, Heufelder A, Zimmermann A. Therapeutic effects and safety of Rhodiola rosea extract WS 1375 in subjects with life-stress symptoms — results of an open-label study. Phytother Res (2012) ; 26 : 1220-1225 . DOI: 10.1002/ptr.3712 . PMID: 22228617
- [11] Lekomtseva Y, Zhukova I, Wacker A. Rhodiola rosea in subjects with prolonged or chronic fatigue symptoms: results of an open-label clinical trial. Complement Med Res (2017) ; 24 : 46-52 . DOI: 10.1159/000457918 . PMID: 28219059
- [12] Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med (2008) ; 14 : 175-180 . DOI: 10.1089/acm.2007.7117 . PMID: 18307390
- [13] Cropley M, Banks AP, Boyle J. The effects of Rhodiola rosea L. extract on anxiety, stress, cognition and other mood symptoms. Phytother Res (2015) ; 29 : 1934-1939 . DOI: 10.1002/ptr.5486 . PMID: 26502953
- [14] De Bock K, Eijnde BO, Ramaekers M, Hespel P. Acute Rhodiola rosea intake can improve endurance exercise performance. Int J Sport Nutr Exerc Metab (2004) ; 14 : 298-307 . DOI: 10.1123/ijsnem.14.3.298 . PMID: 15256690
- [15] Ishaque S, Shamseer L, Bukutu C, Vohra S. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med (2012) ; 12 : 70 . DOI: 10.1186/1472-6882-12-70 . PMID: 22643043
Traditional Texts
- [16] Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: a phytomedicinal overview. HerbalGram (American Botanical Council) (2002) ; 56 : 40-52
- [17] Saratikov AS, Krasnov EA. Rhodiola rosea (Golden Root): A Valuable Medicinal Plant [Родиола розовая - золотой корень]. Tomsk State University Press (original Russian edition 1987; referenced in English reviews) (2004)
- [18] Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone/Elsevier (2013)
Pharmacopeias & Reviews
- [19] Panossian A, Wikman G. Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals (Basel) (2010) ; 3 : 188-224 . DOI: 10.3390/ph3010188 . PMID: 27713248
- [20] Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine (2010) ; 17 : 481-493 . DOI: 10.1016/j.phymed.2010.02.002 . PMID: 20378318
- [21] Hung SK, Perry R, Ernst E. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine (2011) ; 18 : 235-244 . DOI: 10.1016/j.phymed.2010.08.014 . PMID: 21036578
- [22] van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol (2009) ; 122 : 397-401 . DOI: 10.1016/j.jep.2009.01.007 . PMID: 19168123
Last updated: 2026-02-26 | Status: review